AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising ...

A new report by the U.N. AIDS agency says the sudden withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV. Years of American-led investment into AIDS ...

Carlene Pavlos, executive director of the Massachusetts Public Health Association, one of the plaintiffs, said in a statement ...

US biopharma company AbbVie has inked a $700 million deal with IGI Therapeutics to develop and sell ISB 2001, an experimental drug for blood cancer.

Glenmark Share Price: Shares of Glenmark Pharmaceuticals Ltd surged 10 per cent in early trade on Friday, scaling a new ...

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...